Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Dr Mukhtar on Challenges in the Diagnosis and Management of Invasive Lobular Carcinoma

July 20th 2024

Rita Mukhtar, MD, discusses challenges in the diagnosis and management of invasive lobular carcinoma.

Dr Pusztai on Molecular Residual Disease Monitoring in Early Breast Cancer

July 20th 2024

Lajos Pusztai, MD, DPhil, discusses the progress and challenges in monitoring molecular residual disease in early breast cancer.

AE Management and Prevention Strategies for ADCs, Immunotherapy in Breast Cancer

July 19th 2024

Hope Rugo, MD, discusses the management of treatment-limiting toxicities in breast cancer, including the use of antibody-drug conjugates and immunotherapy.

Dr Rugo on Managing Treatment-Limiting Toxicities in Breast Cancer

July 19th 2024

Hope S. Rugo, MD discusses managing treatment-related toxicities within the scope of the current breast cancer treatment paradigm.

Dr Davis on the Utility of ADCs in Breast Cancer

July 18th 2024

Andrew Davis, MD, discusses the use of antibody-drug conjugates in breast cancer, highlighting recent updates with these agents in the treatment paradigm.

Dr Waks on Key Questions Regarding the First-Line Use of T-DXd in HER2+ Breast Cancer

July 17th 2024

Adrienne G. Waks, MD, discusses implications of the potential use of first-line T-DXd in HER2-positive breast cancer.

Emerging Trials in the Management of HR+/HER2- Locally Advanced or Metastatic Breast Cancer

July 16th 2024

Adam M. Brufsky, MD, PhD, and Erika P. Hamilton, MD, share their perspectives on the future landscape of HR+/HER2- locally advanced or metastatic breast cancer treatment and provide essential insights to summarize the key points of their discussion.

Adverse Event Monitoring and Management in HR+/HER2- Locally Advanced and Metastatic Breast Cancer

July 16th 2024

Medical experts address the challenges of managing adverse events in the treatment of HR+/HER2- locally advanced or metastatic breast cancer.

PIK3CA Mutations and Delivering PI3K Inhibitors

July 15th 2024

In their discussion, the key opinion leaders explore the significance of PIK3CA mutations in HR+/HER2- metastatic breast cancer and review the findings from two pivotal clinical trials, SOLAR-1 and CAPItello-291, which investigated the efficacy of targeted therapies in patients harboring these mutations.

Case Presentation 2: Co-mutations in ESR1 and PIK3CA

July 15th 2024

Virginia Kaklamani, MD, DSc, and Heather McArthur, MD, discuss the clinical presentation and management of a 64-year-old postmenopausal female with a history of rheumatoid arthritis who was diagnosed with stage IV, grade 3, invasive ductal carcinoma in her left breast, taking into account her comorbidities and the advanced stage of her breast cancer.

Defining HER2 Low and HER2 Ultra-Low: Diagnostic Challenges

July 15th 2024

Ian Krop, MD, PhD, provides an overview of HER2-low and HER2 ultra-low breast cancer and discusses challenges encountered during diagnosis.

Impact of DESTINY-Breast09 and Other Trials on Clinical Practice and Patient Subsets

July 15th 2024

Experts on breast cancer discuss the potential impact of ongoing research in HER2+ breast cancer, highlighting how results from the DESTINY-Breast07 study may translate to DESTINY-Breast09.

Dr Ma on Questions Regarding Treatment Sequencing in CDK4/6 Inhibitor–Resistant Breast Cancer

July 15th 2024

Cynthia Ma, MD, PhD, discusses unanswered questions regarding treatment sequencing for patients who develop CDK4/6 inhibitor–resistant breast cancer.

Dr Roy on Limitations of the Pathway Trial Evaluating PGS and Survival in Breast Cancer

July 15th 2024

Arya Mariam Roy, MBBS discusses limitations of the Pathway trial evaluating the association between polygenic scores and survival outcomes in patients with breast cancer.

Investigational Agents, Clinical Trials for Advanced HER2+ Breast Cancer

July 12th 2024

Joyce A. O’Shaughnessy, MD, and Neil M. Iyengar, MD, discuss novel agents in the pipeline for patients with advanced HER2-positive breast cancer.

Frequent AEs and Management Approaches for Advanced HER2+ Breast Cancer

July 12th 2024

Joyce A. O’Shaughnessy, MD, and Neil M. Iyengar, MD, discuss commonly reported adverse effects from HER2-positive breast cancer treatment and appropriate management strategies for them.

Treatment Decisions in Advanced HER2+ Breast Cancer With CNS Metastases

July 12th 2024

Joyce A. O’Shaughnessy, MD, and Neil M. Iyengar, MD, discuss how to decide on treatment for patients with advanced or metastatic HER2-positive breast cancer who have central nervous system metastases.

Optimal Management Strategies in Advanced HER2+ Breast Cancer

July 12th 2024

Joyce A. O’Shaughnessy, MD, and Neil M. Iyengar, MD, discuss the various management strategies for treatment of patients with advanced or metastatic HER2-positive breast cancer.

Current Prognosis for Advanced or Metastatic HER2+ Breast Cancer

July 12th 2024

Joyce A. O’Shaughnessy, MD, and Neil M. Iyengar, MD, discuss the prognosis for patients with advanced or metastatic HER2-positive breast cancer.

New Data Augment the Treatment Paradigm in HR+/HER2– Breast Cancer

July 10th 2024

Panelists from an OncLive Peer Exchange detail updated data in the hormone receptor–positive HER2– breast cancer treatment landscape.